Businessweek

n systems for the treatment of uncontrolled hypertension. The company also sells products designed to treat patients with non-vascular disease (disease that appears outside the blood system). Its non-vascular suite of products includes biliary stents, drainage catheters, and micro-puncture sets designed to treat, diagnose, and ease various forms of benign and malignant tumors. The company markets its line of Interventional Oncology product solutions, including the launched Renegade HI-FLO Fathom microcatheter and guidewire system and Interlock - 35 Fibered IDC Occlusion System for peripheral embolization. Neuromodulation Within the company’s Neuromodulation business, it markets the precision spinal cord stimulation (SCS) system, used for the management of chronic pain. This system delivers pain management by applying an electrical signal to mask pain signals traveling from the spinal cord to the brain. The Precision Spectra system is designed to provide improved pain relief to a range of patients who suffer from chronic pain. The company offers its Clik Anchor for its Precision Plus SCS System, a rechargeable SCS device for chronic pain management. The company also markets the Linear 3-4 and Linear 3-6 Percutaneous Leads for use with its SCS systems, which are designed to provide physicians various treatment options for their chronic pain patients. These leads provide the range of percutaneous lead configurations in the industry. Urology/Women’s Health The company’s Urology/Women’s Health division develops, manufactures, and sells devices to treat various urological and gynecological disorders. Within its Urology business, the company sells various products designed to treat patients with urinary stone disease and benign prostatic hyperplasia. It offers a line of stone management products, including ureteral stents, wires, lithotripsy devices, stone retrieval devices, sheaths, balloons, and catheters. Within its Women's health business, the company markets a range of devices for the treatment of conditions, such as female urinary incontinence, pelvic floor reconstruction (rebuilding of the anatomy to its original state), and menorrhagia (excessive menstrual bleeding). The company offers a breadth of mid-urethral sling products, sling materials, graft materials, pelvic floor reconstruction kits, and suturing devices. It markets its Genesys Hydro ThermAblator system, a next-generation endometrial ablation system designed to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia. Electrophysiology Within the company’s Electrophysiology business, it develops less-invasive medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart. Included in the company’s product offerings are radio frequency (RF) generators, steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Its products include the Blazer and Blazer Prime line of temperature ablation catheters, designed to deliver improved performance, responsiveness, and durability. The company’s cooled ablation portfolio includes the only closed-loop irrigated catheter on the market, the Chilli II cooled ablation catheter, and the newly launched Blazer Open-Irrigated ablation catheter with a Total Tip Cooling Design. Additionally, in 2012, the company acquired Rhythmia Medical, Inc., a developer of next-generation mapping and navigation solutions for use in cardiac catheter ablations and other electrophysiology procedures, including atrial fibrillation and atrial flutter. Cardiac Rhythm Management The company develops, manufactures, and markets various implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, including implantable cardioverter defibrillator (ICD) systems used to detect and treat abnormally fast heart rhythms (tachycardia) that could result in sudden cardiac death, including the commercially available subcutaneous implantable cardioverter defibrillator - the S-ICD System, and implantable cardiac resynchronization therapy defibrillator systems used to tr